# A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

> **NCT06417008** · PHASE2,PHASE3 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 1080 (estimated)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** HS-20117
- **DRUG:** Aumolertinib

## Key facts

- **NCT ID:** NCT06417008
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-28
- **Primary completion:** 2026-06-01
- **Final completion:** 2030-06-01
- **Target enrollment:** 1080 (ESTIMATED)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06417008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06417008, "A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06417008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*